文献速递骨质疏松与钙磷/甲状旁腺

地舒单抗治疗时长影响后续唑来膦酸维持骨密度的疗效

The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

这项多中心前瞻性队列研究纳入47例绝经后女性,在末次地舒单抗注射6个月后给予单次唑来膦酸输注并随访1年。结果显示,接受≤6次地舒单抗者腰椎骨密度维持,而>6次者显著下降,且治疗时长与腰椎骨密度变化百分比负相关。

要点

  • 地舒单抗使用≤6次后换用唑来膦酸可维持腰椎骨密度。
  • 使用>6次地舒单抗者唑来膦酸后腰椎骨密度仍显著下降。
  • 地舒单抗治疗超过3年者需密切随访,可能需额外治疗。

核心结论

  • 地舒单抗治疗时长显著影响后续唑来膦酸输注维持骨密度增益的疗效。

研究设计与样本

  • 多中心前瞻性队列研究,在希腊2个和荷兰1个骨中心进行,纳入47例绝经后女性。
  • 所有患者在末次地舒单抗注射6个月后接受单次唑来膦酸输注,随访1年。

主要发现

  • 12个月时腰椎骨密度在≤6组维持(0.98 ± 0.10至0.99 ± 0.9 g/cm2,P = 0.409)。
  • 12个月时腰椎骨密度在>6组显著下降(1.0 ± 0.11至0.93 ± 0.12 g/cm2,P < 0.001)。
  • ≤6组腰椎骨密度百分比变化(+1.0%)与>6组(-7.0%)差异显著(P < 0.001)。
  • 全队列中地舒单抗治疗时长与腰椎骨密度百分比变化负相关(rs = -0.669,P < 0.001),但与股骨颈骨密度变化无关。
  • 唑来膦酸给药6个月后所有患者骨转换标志物升高,两组间无差异。

临床怎么用

  • 地舒单抗使用超过3年的患者应频繁随访,可能需要额外治疗干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Zoledronate is used to prevent bone loss following denosumab discontinuation but its efficacy differs among studies. OBJECTIVE: To test if the duration of denosumab treatment affects the efficacy of subsequent zoledronate infusion. METHODS: This multicenter, prospective cohort study, conducted at 2 Greek and 1 Dutch bone centers, included 47 postmenopausal women (n = 47) who received a single zoledronate infusion 6 months after the last denosumab injection and then were followed for 1 year. Twenty-seven women received ≤ 6 denosumab injections (≤ 6 Group) and 20 received > 6 denosumab injections (> 6 Group). The main outcome measure was changes in lumbar spine (LS) bone mineral density (BMD). RESULTS: At 12 months LS-BMD values were maintained in the ≤ 6 Group (0.98 ± 0.10 to 0.99 ± 0.9 g/cm2, P = 0.409) but decreased significantly in the > 6 Group (1.0 ± 0.11 to 0.93 ± 0.12 g/cm2, P < 0.001). The percent change of LS-BMD of the ≤ 6 Group (+1.0%) was significantly different (P < 0.001) from the change of the > 6 Group (-7.0%). In the whole cohort, the duration of denosumab treatment was negatively correlated with the percentage change of LS-BMD (rs = -0.669, P < 0.001) but not with the change of femoral neck (FN)-BMD. Bone turnover markers increased in all patients 6 months following zoledronate administration with no difference between the 2 groups. CONCLUSION: The duration of denosumab treatment significantly affects the efficacy of subsequent zoledronate infusion to maintain BMD gains. Frequent follow-up of patients treated with denosumab longer than 3 years is advisable as additional therapeutic interventions may be needed.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Makras P, Appelman-Dijkstra NM, Papapoulos SE, et al. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. J Clin Endocrinol Metab. 2021. PMID: 33978745. doi:10.1210/clinem/dgab321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。